What is the appropriate management and treatment for Wilson disease?

Management and Treatment of Wilson Disease

Wilson disease requires lifelong pharmacological treatment with copper chelators (D-penicillamine or trientine) or zinc salts, with chelators being the mandatory first-line choice for patients with significant liver disease. 1, 2

Initial Treatment Selection

For Hepatic Presentations

• Start with chelation therapy (D-penicillamine or trientine) for any patient with symptomatic liver disease, as zinc alone is insufficient for significant hepatic involvement 1, 2
• D-penicillamine remains effective with recovery of synthetic liver function typically occurring within 2-6 months, though improvement may continue through the first year 1
• Consider trientine as first-line therapy if the patient has risk factors for D-penicillamine intolerance: history of renal disease, severe thrombocytopenia from congestive splenomegaly, or autoimmune tendency 1
• Trientine has proven effective even in decompensated liver disease at presentation 1

For Neurological Presentations

• Exercise extreme caution with D-penicillamine in neurological Wilson disease, as 13.8% experience paradoxical neurological worsening during initial treatment 1
• Neurological deterioration occurs with all three treatments but predominantly with D-penicillamine 1
• Trientine causes neurological worsening much less commonly than D-penicillamine and should be strongly considered for neurological presentations 1
• Neurological improvement is slower than hepatic recovery and may continue for up to three years 1

D-Penicillamine Dosing and Administration

Initial Dosing Strategy

• Start with incremental dosing: 125-250 mg/day, increasing by 250 mg every 4-7 days to maximum 1000-1500 mg/day in 2-4 divided doses 1
• Never administer ≥1500 mg/day at once, as this leads to rapid and often irreversible neurological deterioration 1
• Rapid re-administration after prolonged cessation can also trigger irreversible neurological signs 1
• Administer on empty stomach (absorption decreases 50% with food) 1
• Supplement with pyridoxine 25-50 mg daily 1

Critical Side Effects Requiring Immediate Discontinuation

• Early sensitivity reactions (first 1-3 weeks): fever, cutaneous eruptions, lymphadenopathy, neutropenia, thrombocytopenia, proteinuria 1
• Severe bone marrow toxicity: severe thrombocytopenia or total aplasia 1
• Nephrotoxicity: proteinuria or cellular elements in urine 1
• Approximately 30% of patients require discontinuation due to severe side effects 1

Trientine Dosing and Administration

• Typical dosing: 750-1500 mg/day in 2-3 divided doses 1
• Maintenance therapy: 750-1000 mg/day 1
• Pediatric dosing: 20 mg/kg/day rounded to nearest 250 mg in 2-3 divided doses 1
• Administer 1 hour before or 2 hours after meals (closer timing acceptable if it ensures compliance) 1
• Do not co-administer with iron as the iron-trientine complex is toxic 1
• Trientine has minimal side effects compared to D-penicillamine, with no hypersensitivity reactions reported 1

Zinc Therapy

• Reserve zinc for maintenance therapy in stable patients, not as first-line treatment for symptomatic disease 1, 2
• Mechanism: induces enterocyte metallothionein, which binds dietary copper and prevents absorption 1
• Neurological deterioration is uncommon with zinc compared to chelators 1
• Gastric irritation is the main side effect 1

Treatment Monitoring

Monitoring Frequency

• Minimum twice yearly for stable patients 1
• More frequent during initial treatment phase, symptom worsening, medication side effects, or suspected non-compliance 1

Laboratory Targets on Chelation Therapy

24-hour urinary copper excretion:

• Initial treatment: may exceed 1000 µg (16 µmol)/day 1
• Maintenance target: 200-500 µg (3-8 µmol)/day 1
• Values <200 µg/day suggest either non-adherence or overtreatment 1

Non-ceruloplasmin bound copper:

• Target: 50-150 µg/L during effective treatment 1
• Elevated (≥150 µg/L) with low urinary copper indicates non-adherence 1
• Very low (<50 µg/L) with low urinary copper indicates overtreatment 1
• Recent data suggests clinically stable patients frequently have NCC below recommended ranges without signs of copper deficiency, calling for re-evaluation of targets 3

Additional monitoring:

• Liver biochemistries and synthetic function 1
• Complete blood count (for chelator-induced cytopenias) 1
• Urinalysis (for proteinuria on D-penicillamine) 1
• Kayser-Fleischer ring examination (reappearance indicates non-compliance) 1

Zinc Therapy Targets

• 24-hour urinary copper: ≤75 µg (1.2 µmol)/day 1
• 24-hour urinary zinc: approximately 2 mg/day 1

Critical Pitfalls

• Never stop treatment: discontinuation leads to hepatic failure within 1-12 months, resulting in death or need for transplantation 1
• Avoid high-dose D-penicillamine initiation in neurological patients 1
• Do not use prednisone co-treatment for D-penicillamine sensitivity reactions; alternative medications are available 1
• Monitor for overtreatment: can cause reversible sideroblastic anemia and hemosiderosis with both D-penicillamine and trientine 1
• Trientine tablets are unstable at high ambient temperatures 1

Liver Transplantation

• Well-defined role in Wilsonian acute liver failure 2
• May be considered in severe neurological disease, though outcomes are variable 1, 2
• Patients with neurological/psychiatric manifestations may have poorer post-transplant outcomes and adherence difficulties 1